- A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism
- A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism
- A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism – A Clinical Extension Study (RACE)
- A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism
- A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
- A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism – A Clinical Extension Study in Hungary
- A Survey to Assess Participants’ and Physicians’ Knowledge, Attitudes and Behavior When Using NATPARA
- A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism
- A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
- ADD-ON Study to Existing Hypoparathyroidism Studies
- AZP-3601 SAD and MAD Study in Healthy Subjects and Subjects With Hypoparathyroidism
- Bone Properties in Hypoparathyroidism: Effects of PTH
- Burden of Illness in Hypoparathyroidism
- Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
- Corticosteroid Rhythms in Hypoparathyroid Patients
- Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.
- Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism
- Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism (EMPATHY)
- Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
- Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
- HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism
- Magnesium Treatment in Hypoparathyroidism
- Near-infrared Autofluorescence (NIRAF) in Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Centers
- Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism
- Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism
- PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
- Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test After Total Thyroidectomy
- Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy
- Predicting Risk Factors of Postoperative Hypocalcemia After Total Thyroidectomy
- Preoperative Lugol’s Solution in Graves’ Disease and Toxic Nodular Goiter
- Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy (Qol-Hypopara)
- Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism
- Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
- Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects
- Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
- Study of the Effect of Recombinant Human Parathyroid Hormone [rhPTH(1-84)] on Symptoms Improvement and Metabolic Control Among Adults With Hypoparathyroidism
- Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism
- Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life
- Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
- Use of NPSP558 in the Treatment of Hypoparathyroidism
- Vitamin D Levels and Postoperative Hypocalcemia After Total Thyroidectomy
Clinical Trials
- Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract
- Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer
- Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma
- Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
- New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma
- Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy
- Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer
- Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation
- Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery
- Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer
- Study Assessing The “Best of” Radiotherapy vs the “Best of” Surgery in Patients With Oropharyngeal Carcinoma
- A Prospective Sub-Study of the Global Hypophosphatasia Registry
- An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)
- Burden of Disease in Hypophosphatasia (HPP)
- Characterisation of Adult-Onset Hypophosphatasia
- Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia
- Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)
- Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia
- Evaluation of Bone Architecture and Bone Strength in Adults With Hypophosphatasia (HPP)
- Health Burden of Hypophosphatasia
- Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
- Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
- Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)
- Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease
- Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)
- Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
- The PORTRAIT Study
- United States Hypophosphatasia Molecular Research Center
- Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)
- A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults
- Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium
- Androgen Replacement Therapy in Women With Hypopituitarism
- Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys
- Central Hypothyroidism and Cardiovascular Risk
- Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency
- Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients
- Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
- Effect of 5 Years of GH Replacement on Atherosclerosis
- Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency
- Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients
- Growth Hormone Replacement Therapy for Retried Professional Football Players
- Hormone Deficiency After Brain Injury During Combat
- Hypopituitarism After Aneurismal Subarachnoid Hemorrhage
- Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)
- Lipolytic Effects of GH in Hypopituitary Patients in Vivo
- Next Day Growth Hormone Predicting Pituitary Function After Adenomectomy
- Oestrogen Withdrawal in Hypopituitary Women
- Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation
- Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
- Posttraumatic Hypopituitarism – Incidence, Predictors and Test Validity
- Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes
- Testosterone and Growth Hormone for Bone Loss in Men
- The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin
- The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism
- An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
- Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency
- Pharmacodynamics of CNP During Growth Hormone Treatment
- Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
- A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
- A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
- A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
- A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
- Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
- Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
- Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
- Eosinophilia Diagnosis
- Identification of New Markers in the Hypereosinophilic Syndrome
- Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
- MAP to Provide Access to Nilotinib, for Patients With HES
- Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
- Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
- Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
- Steroid Treatment for Hypereosinophilic Syndrome
- Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
- Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old
- Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
- Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome
- This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic
- Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
- “Steroids and Azathioprine Versus Steroids Alone in IgAN”
- A Clinical Research on the Use of Fecal Bacteria Transplantation for Treatment of IgA Nephropathy
- A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
- A Phase 2 Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label LNP023 in Patients With Primary IgA Nephropathy
- A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
- A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) Nephropathy
- A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
- A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
- A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
- A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject
- A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy
- Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers
- Aliskiren for Immunoglobulin A (IgA) Nephropathy
- Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade
- An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)
- An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
- Atacicept in Subjects With IgA Nephropathy
- Atrasentan in Patients With IgA Nephropathy
- Atrasentan in Patients With Proteinuric Glomerular Diseases
- Biomarkers for the Progression of IgA Nephropathy
- Bortezomib for Treating Glomerular Diseases
- BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
- BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
- Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy
- Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
- Correlation of Microbiome and Metabonomics With IgA Nephropathy
- Diet Intervention in Food Sensitive Patients With IgA Nephropathy
- Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy
- Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy
- Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
- Efficacy and Safety of Atacicept in IgA Nephropathy
- Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy
- Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
- Fecal Microbiota Transplantation for Refractory IgA Nephropathy
- First in Human Study to Assess Safety of VIS649 in Healthy Subjects
- IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
- IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
- IgA Nephropathy, Lymphocyte Homing and IgA Class Switch
- Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy
- KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
- Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
- Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
- Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
- Mycophenolate Mofetil for IgA Nephropathy
- Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy
- Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
- Open-Label Extension Study of BION-1301 in IgA Nephropathy
- Oral Treatment With PL-56 in Patients With IgA Nephropathy – an Explorative Study
- Oxford Classification and Clinical Remission After Initial Treatments in Patients With IgA Nephropathy
- Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
- Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
- Phase III Study of Telitacicept in Patients With IgA Nephropathy
- Pilot Study of Velcade® in IgA Nephropathy
- Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
- Probiotics in IgA Nephropathy
- Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
- Registry of IgA Nephropathy in Chinese Children
- Rituximab and RASi in Patients With IgAN
- Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
- Rituximab in Recurrent IgA Nephropathy
- Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
- Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
- Safety and Efficacy Study of VIS649 for IgA Nephropathy
- Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
- Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
- Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy
- Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy
- SodiUm Restriction by Behavioral Intevention
- Steroids and Azathioprine in Advanced IgAN
- Steroids Therapy in IgA Nephropathy With Crescents
- Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
- Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
- Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
- Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
- Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath
- Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
- Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
- The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients
- The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy
- The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients
- The Role of T/B Cell Repertoire in Non-invasive Diagnosis and Disease Monitoring in Patients With IgA Nephropathy
- Treatment of IgA Nephropathy According to Renal Lesions
- Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.
- Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
- Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy
- A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)
- A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
- An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
- Arimoclomol in Sporadic Inclusion Body Myositis
- Arimoclomol in Sporadic Inclusion Body Myositis – Open Label Extension Trial
- Blood-flow Restricted Exercise in Inclusion Body Myositis
- Cell Therapy for IBM by Muscle Injection of ADSVF: a Phase I Trial
- Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
- Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
- Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
- Establishing Muscle Impedance Parameters With Electrical Impedance Myography
- Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
- Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells
- Lithium in Inclusion Body Myositis (IBM)
- Molecular Profile of the Evolution of Inclusion Body Myositis
- Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
- Natalizumab in Inclusion Body Myositis (IBM)
- Natural History in CCFDN and IBM Syndromes
- Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study
- Phase III Trial of Sirolimus in IBM
- Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
- Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
- Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
- Sporadic Inclusion Body Myositis Natural History Study
- Study of Arimoclomol in Inclusion Body Myositis (IBM)
- Study of Pioglitazone in Sporadic Inclusion Body Myositis